LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a target name.
REQUEST A FREE TRIAL
Pipeline
Deals
Financings
Articles
BioCentury
|
Oct 7, 2024
Distillery Therapeutics
Inhibiting Factor XII for diabetic kidney disease
Read More
BioCentury
|
May 24, 2024
Product Development
Clinical Report: Merus data stand out among ASCO highlights
Clinical data released ahead of ASCO from Merus, Caribou, BioNTech and more
Read More
BioCentury
|
Mar 8, 2024
Product Development
Pfizer blends modality tools in new vision for oncology unit
Pharma outlines goals for oncology business as it moves to integrate ADC play Seagen
Read More
BioCentury
|
Mar 5, 2024
Discovery & Translation
Distillery spotlight: new Alzheimer’s mechanisms from academia
BioCentury’s survey of the 2023 translational literature highlights a cluster of neuron-targeting mechanisms for Alzheimer’s disease
Read More
BioCentury
|
Oct 2, 2023
Regulation
Oct. 2 Quick Takes: Takeda withdrawing Exkivity after confirmatory miss
Plus: Novartis’ iptacopan shows benefit in IgA nephropathy and updates from Mirum, Lexeo, Rocket, Lilly, Syndax, SAB, Amicus and Pneumagen
Read More
BioCentury
|
Apr 21, 2023
Product Development
ADC advances at AACR: target diversity, optimizing internalization
BioCentury’s analysis of the AACR 2023 abstracts highlights innovation in antibody-drug conjugate design
Read More
BioCentury
|
Mar 13, 2023
Deals
Pfizer believes $43B Seagen deal positions it to fulfill most of 2030 revenue goal
Provided regulators clear deal, pharma sees $10B+ in added revenue from ADC company by early next decade
Read More
BioCentury
|
Jan 7, 2022
Distillery Therapeutics
Supramolecular polymers for spinal cord injury
Read More
BioCentury
|
Mar 13, 2021
Translation in Brief
NIH identifies antisense oligos to treat progeria; plus epigenetic gene therapies for chronic pain and Cend’s pancreatic cancer therapy
BioCentury’s roundup of translational news
Read More
BioCentury
|
Aug 28, 2020
Distillery Therapeutics
Preventing thrombosis using nanoparticles loaded with anti-G protein peptides
DISEASE CATEGORY: Cardiovascular
INDICATION: Ischemia/reperfusion injury Nanoparticles loaded with a peptide inhibitor of GNA13, a G protein subunit, could treat cardiac ischemia/reperfusion injury.
Read More
Items per page:
10
1 - 10 of 55